Skip to content

Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease

Assessment of Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (CKD) After the Implementation of a Nutritional Education Plan and Individualized Dietary Intervention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05072574
Acronym
ERCANUT
Enrollment
54
Registered
2021-10-11
Start date
2021-04-23
Completion date
2022-12-31
Last updated
2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Keywords

Advanced CKD, diet, nutritional education, coaching, quality of life (QoL), nutritional status, functional capacity

Brief summary

This study evaluates the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.

Detailed description

Randomized study including two parallel groups: patients from the advanced chronic kidney disease (CKD) consulting room of the Malaga University Regional Hospital and controls. The main objective is to assess the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit. Both groups will be composed of 54 participants. The control group will be provided general dietary and lifestyle recommendations (standard procedure in the nephrology consulting room), whereas the intervention group will receive treatment and individualized dietary follow-up using coaching techniques, supported by information and communication technologies, and will participate in a nutritional education program composed of four on-line sessions. Two visits (basal and three months after) will be scheduled during the study to obtain and analyse the data. Moreover, in these visits researchers will collect a blood sample in order to perform an assessment of the metabolism, inflammation, and oxidation, and a stool sample in order to evaluate the gut microbiota.

Interventions

OTHERSpecific dietary treatment and follow-up using coaching techniques

Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program

Sponsors

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients will be randomized in a 1:1 ratio

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients \>18 years old with advanced CKD (GFR \<30ml/min) starting follow-up in the advanced CKD consulting room of the Malaga University Regional Hospital and who clearly understand the study and give their informed consent.

Exclusion criteria

* Patients presenting any of these conditions: * Active cancer * Being already participants of another study that may affect the results * Pregnancy or possible pregnancy * Informed consent refusal * Hospital admission during one month previous to the study * Severe mental disorders (SMD), prolonged mental disorders involving a high level of disability and social dysfunction, which requires attendance by the mental health and social care network * Alcohol or any other substance abuse that, in the researcher's opinion, may interfere with the study

Design outcomes

Primary

MeasureTime frameDescription
Assess the clinical response after the quality of life interventionFrom baseline to week 12Kidney Disease and Quality of Life test (KDQOL-36). The generic component of the KDQOL-36 (items 1-12) is the SF-12, which allows obtaining 2 general scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The specific component of the KDQOL-36 (items 13-36), allows obtaining the scores of the specific subscales for the disease.

Secondary

MeasureTime frameDescription
Assess the clinical response after the intervention in knowledge about the diseaseFrom baseline to week 12Kidney Disease Knowledge Survey test. The Kidney Disease Knowledge Survey (KiKS) instrument consists of 28 items and aims to assess specific knowledge about chronic kidney disease in non-dialysis patients. One point is considered for each correct answer and zero for the incorrect one. The total score is calculated by adding all the correct points and divided by 28, obtaining a value from 0 to 1, with 1 being the highest level of knowledge.
BMI (body mass index) changesFrom baseline to week 12Measured by body composition analysis
Change in weightFrom baseline to week 12Weight in kg
Change in fat free body massFrom baseline to week 12Fat free body mass in kg assessed by bioelectrical impedance analysis
Change in upper arm circumferenceFrom baseline to week 12circumference in cm
Change in arm muscle circumferenceFrom baseline to week 12circumference in cm
waist circumferenceFrom baseline to week 12circumference in cm
Change in serum potassium concentration (assess kidney function)From baseline to week 12serum potassium in mEq/l
Change in serum phosphorus concentration (assess kidney function)From baseline to week 12serum phosphorus mg/dl
Change in glomerular filtration (assess kidney function)From baseline to week 12Calculated with the formula of CKD-EPI and MDRD and measured in ml/ min/ 1.73 m2
Change in serum albumin concentrationFrom baseline to week 12Serum albumin in g/dl
Change in serum prealbumin concentrationFrom baseline to week 12Serum prealbumin in mg/dl
Change in cholesterol concentrationFrom baseline to week 12Serum cholesterol in mg/dl
Change in HDL concentrationFrom baseline to week 12Serum HDL in mg/dl
Change in LDL concentrationFrom baseline to week 12Serum LDL in mg/dl
Change in TG concentrationFrom baseline to week 12Serum TG in mg/dl
Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)From baseline to week 12Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl
Changes in blood cellsFrom baseline to week 12Blood count
Assess the clinical response after intervention in the management of CKDFrom baseline to week 12Self-Efficacy for Managing Chronic Disease test. The Self-Efficacy Scale for the Management of Chronic Diseases (SEMCD) is made up of 6 items on an analog scale, ranging from 1 (not at all sure) to 10 (totally safe). The Spanish version (SEMCD-S) consists of 4 items. A higher number means greater self-efficacy. The scale score is the mean of the items.
Change in ferritin concentrationFrom baseline to week 12Serum ferritin in ng/ml
Change in uric acid concentrationFrom baseline to week 12Serum uric acid in mg/dl
Change in urea concentrationFrom baseline to week 12Serum uric acid in mg/dl
Change in magnesium concentrationFrom baseline to week 12Serum magnesium in mg/dl
Change in calcium concentrationFrom baseline to week 12Serum calcium in mg/dl
Change in intact parathyroid hormone (PTHi) concentrationFrom baseline to week 12Serum intact parathyroid hormone (PTHi) in pg/ml
Changes in vitamin DFrom baseline to week 12Serum vitamin D in ng/ml
Changes in metabolic controlFrom baseline to week 12Measured as HbA1c (glycated hemoglobin)
Assess changes in the degree of depression and / or anxietyFrom baseline to week 12HADS depression and anxiety symptoms screening test. It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them. Based on the score obtained, the patients can be classified as normal (\<7), doubtful (between 8 and 10) and potential clinical case (≥ 11). The score is referred to the last week.
Assess the clinical response after the intervention on functional capacityFrom baseline to week 12Scale of autonomy for activities of daily life Barthel test. This test measures the capacity of the person to carry out ten basic activities of daily life, obtaining a quantitative estimate of the degree of dependence of the subject. The range of possible IB values is between 0 and 100, with 5-point intervals for the original version. The closer a subject's score is to 0, the more dependency they have; the closer to 100 the more independence.
Assess on functional capacityFrom baseline to week 12Physical activity test Short Physical Performance Battery SPPB. This in turn includes 3 tests: balance, gait speed and getting up and sitting in a chair 5 times. Each test is scored from 0 (worst performance) to 4 (best performance): for the balance test according to a hierarchical combination of performance in the 3 component subtests and for the other 2 tests a score of 0 is assigned to those who do not complete or they attempt the task and scores from 1 to 4 based on the time spent. In addition, a total score for the entire battery is obtained, which is the sum of the 3 tests and ranges from 0 to 12.
Changes on functional capacity: International Physical Activity Questionnaire (IPAQ)From baseline to week 12The International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. The survey consists of 27 questions and 5 parts.
Change from Handgrip StrengthFrom baseline to week 12Strength will be recorded by Jamar Hydraulic Hand Dynamometer (Kg)
Characterize exercise participant behaviorFrom baseline to week 12International Physical Activity Questionnaire (IPAQ). The IPAQ consists of 7 questions about the frequency, duration and intensity of activity (moderate and intense) carried out in the last seven days, as well as walking and sitting time in a work day. It evaluates three characteristics of physics (PA): intensity (mild, moderate or vigorous), frequency (days per week) and duration (time per day). Weekly activity is recorded in Mets (Metabolic Equivalent of Task or Metabolic Index Units) per minute and week.
Change in handgrip strengthFrom baseline to week 12Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.
Changes the clinical response after the intervention in blood pressure figures (mmHg).From baseline to week 12Assess if syastolic and diastolic pressure improves after training and at 6 months of follow-up.
Diet composition: PREDIMED test (Prevention with Mediterranean Diet)From baseline to week 12Adherence to the Predimed Plus diet pattern 17 (0 - minimum adherence, 17 - maximum adherence)
Change in iron concentrationFrom baseline to week 12Serum iron in μg/dl

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026